What happened with MNPR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Monopar Therapeutics is developing ALXN1840, an investigational once-daily oral treatment for Wilson disease, and the MNPR-101 radiopharmaceutical program for advanced cancers. MNPR-101 uses an antibody that targets uPAR on tumors; its candidates are being developed for cancer imaging and treatment and remain in clinical or preclinical studies. The company plans to submit a marketing application for ALXN1840, but regulators could require further studies.
Monopar has no approved drugs and has generated no revenue. Potential income would come from selling approved medicines, licensing or selling candidates, or arranging commercialization with partners. Drug sales would depend on coverage and reimbursement from government and private payers. For now, Monopar relies on financing to fund development, rather than customer payments.
ALXN1840 comes from an exclusive worldwide license from Alexion, which is entitled to milestone payments, sales royalties and a share of sublicensing income. Monopar must obtain regulatory approval before selling any treatment. It also relies on outside manufacturers: its radiopharmaceuticals cannot be stockpiled and require prompt shipment, while development of MNPR-101-Ac depends on access to actinium-225 supplied by NorthStar.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Monopar’s prospects hinge on ALXN1840 approval and progress in cancer radiopharmaceuticals, with NorthStar’s actinium-225 supply and CuraSight’s competing uPAR programs worth watching.
Ultragenyx Pharmaceutical Inc.’s UX701 gene therapy competes with Monopar’s ALXN1840 as an investigational treatment for Wilson disease: two different approaches seeking to treat the same patients.
Radiopharm Theranostics Limited competes with Monopar in developing drugs that use radioactive isotopes to image and treat solid tumors. Like Monopar, it has no approved products for sale, so watch its clinical progress rather than product revenue.
Telix Pharmaceuticals Limited already sells cancer imaging agents and is developing radioactive treatments that compete with Monopar’s imaging-and-treatment strategy. Watch sales of Illuccix and Gozellix, its prostate-cancer imaging agents supplied through commercial and hospital radiopharmacies, for evidence of demand in a market Monopar has yet to enter.
Actinium Pharmaceuticals, Inc competes with Monopar in using antibodies to deliver radiation to treatment targets, though its main targets and diseases differ from Monopar’s uPAR-targeted solid tumors. Its clinical work on CD33- and CD45-targeting therapies offers a comparison for antibody-directed radiation treatment, not a direct test of Monopar’s approach.
Lantheus Holdings, Inc sells radioactive cancer diagnostics and develops programs Monopar names as competition for MNPR-101, supplying mainly U.S. hospitals, independent imaging centers and government facilities. Watch its PYLARIFY manufacturing network: multiple approved sites give it production flexibility and supply options that matter when delivering imaging drugs.
AstraZeneca PLC is both the source of Monopar’s lead Wilson-disease candidate, licensed through Alexion, and a competitor developing cancer radiopharmaceuticals. If Monopar sublicenses ALXN1840, Alexion has first-negotiation rights and receives 35%–45% of sublicensing income, directly affecting what Monopar keeps from a deal.
Novartis AG’s established business in targeted radioactive cancer treatments competes for treatment adoption with the therapies Monopar is still developing.
Novartis AG earningsNVS
Novartis’s report can show how its targeted radioactive cancer-treatment business is progressing, a competitive reference point for Monopar’s still-developing cancer programs.
Look for progress in Novartis’s targeted radioactive cancer-treatment business and signs of treatment adoption. Progress would show that Monopar’s MNPR-101 programs face an established business competing for adoption; setbacks would soften that competitive signal but would not show whether Monopar’s candidates work.
Ultragenyx Pharmaceutical Inc. earningsRARE
Ultragenyx’s report can show whether its Wilson disease gene-therapy program is advancing, giving Monopar a read on competition for the same patients as ALXN1840.
Look for clinical progress on UX701. If the program advances, patients ALXN1840 is intended to treat have another developing treatment option, raising the competitive bar; if it is delayed or set back, immediate competitive pressure eases, but ALXN1840’s own regulatory and efficacy questions remain.
Lantheus Holdings, Inc earningsLNTH
Lantheus’s report can show how its multi-site PYLARIFY production supports supply, a practical delivery benchmark for Monopar’s MNPR-101-Zr program.
Look for PYLARIFY supply capacity and reliability across Lantheus’s production network. Dependable supply from multiple sites would show how manufacturing flexibility helps get imaging drugs to users; constraints would highlight the delivery risk for short-lived MNPR-101-Zr, which Monopar says must be made as needed and shipped almost immediately.
Monopar Therapeutics Inc. earningsThis company
Monopar Therapeutics has no drug-sale revenue, so this report shows how quickly research and operating costs are using the cash that funds its drug programs.
Read operating cash use alongside spending and progress on ALXN1840 and the MNPR-101 programs. If cash use stays contained while the programs advance, Monopar has more room to reach the next development steps before needing more funds; if cash use rises or work slows, its expected runway may shorten and it may need financing, partnerships or narrower development plans sooner.
